Figure S9 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Key Points

• Combination treatment using PRMT5 and KRAS inhibitors effectively targets pancreatic cancer with specific genetic mutations.
• Overrepresentation analysis indicates significant efficacy of treatments involving PRMT5i and G12Di in mutant cases.
• The findings suggest a promising strategy for improving treatment outcomes in patients with MTAP-deleted KRAS-mutant pancreatic cancer.
• Further research is necessary to fully understand the mechanisms of action and optimize treatment protocols.

Abstract